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oes the Concept Need to Be Rescued?*
indy L. Grines, MD, FACC,
illiam W. O’Neill, MD, FACC
oyal Oak, Michigan
uring the 1980s, thrombolytic therapy became the initial
reatment for patients with acute myocardial infarction
AMI). Toward the end of the decade, primary percutane-
us coronary intervention (PCI) was shown to be effective
1,2), and a recent analysis of 23 randomized trials demon-
trated improved rates of reinfarction, stroke, and death
ompared with thrombolytic therapy (3). However, because
f limited facilities and trained interventionists, many hos-
itals continue to initiate thrombolytic therapy for patients
ith AMI.
See page 287
Unfortunately, not all arteries respond to thrombolytic
herapy, and approximately 40% have less than Thrombol-
sis In Myocardial Infarction (TIMI) flow grade 3 after 90
in. Patients with an occluded infarct artery (TIMI flow
rade 0 to 1) or suboptimal flow (TIMI flow grade 2) 90
in after thrombolytic therapy have worse left ventricular
LV) function and increased early mortality (4). Rescue PCI
s performed for patients with failed thrombolysis to estab-
ish reperfusion, to salvage myocardium, and hopefully to
mprove prognosis.
A post hoc analysis of patients from the Thrombolysis
nd Angioplasty in Myocardial Infarction (TAMI) trials
emonstrated that the in-hospital and late mortality of
atients who left the catheterization laboratory with a
atent infarct artery were similar in groups who had
eperfusion established by successful thrombolysis (n 607)
r by rescue PCI after failed thrombolysis (n  169) (5).
owever, patients requiring rescue PCI to achieve patency
ad a twofold greater rate of reocclusion, which was
ssociated with less regional and global LV functional
ecovery. Moreover, in patients who failed rescue PCI, the
ortality was 39%.
In a review of 12 early observational studies (6), short-
erm patency was restored by rescue PCI in 71% to 100% of
ccluded coronary arteries after failed thrombolysis (mean,
0%). However, 18% of vessels reoccluded, ejection fraction
ften failed to improve by hospital discharge, and in-
ospital mortality averaged 10.6%. Over the years, better
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Division of Cardiology, William Beaumont Hospital, Royal Oak,iichigan.nderstanding of the importance of aspirin, higher-dose
eparin, and angioplasty technique have resulted in lower
eocclusion rates. In the Global Utilization of Streptokinase
nd t-PA for Occluded Coronary Arteries (GUSTO) an-
iographic substudy, there was no difference in immediate
atency or in-hospital reocclusion among various thrombo-
ytic regimens (7). Likewise, reocclusion at 24 h occurred in
nly 4% of patients having TIMI flow grade 3 (8).
Few randomized trials of rescue PCI have been reported
9–13). In the TAMI-5 study group (9), 575 thrombolytic
atients were randomized to either immediate angiography
ith rescue PCI for failed thrombolysis or a deferred
redischarge catheterization strategy. Rescue PCI was per-
ormed in 18% of the immediate group with an 85% success
ate. As a result, 96% of the immediate catheterization
roup left the catheterization laboratory with a patent
nfarct artery. At hospital discharge, the immediate angio-
lasty group had greater predischarge patency, improved
egional motion in the infarct zone, and a reduced rate of
ecurrent ischemia. Immediate catheterization appeared to
e safe, with similar nadir hematocrit and transfusion
equirement between the two groups.
In the multicenter international Randomized Evaluation
f Salvage angioplasty with Combined Utilization of End-
oints (RESCUE) study, 151 anterior myocardial infarction
MI) patients with angiographically documented TIMI flow
rades 0 to 1 after lytic therapy were randomized to either
escue PCI or medical therapy (10). The benefits of rescue
CI were most likely underestimated by this study as a
esult of the exclusion of patients with previous MI by
rotocol and investigator bias to dilate (and therefore not to
andomize) 134 other high-risk patients with left anterior
escending occlusion. Despite this, at 30 days, the patients
ndergoing rescue PCI had a higher exercise ejection
raction (45% vs. 40%, p  0.04) and a reduction in the
ombined end point of death or New York Heart Associa-
ion functional class III to IV heart failure (6.4% vs. 16.6%,
 0.05). These differences were apparent up to one year of
ollow-up.
In the late 1990s, two European studies were conducted
omparing three different management strategies in AMI
atients who were admitted to hospitals without a cathe-
erization laboratory (12,13). Although transfer for primary
CI was the best approach, patients who were randomly
ssigned to thrombolysis with routine transfer for rescue
CI demonstrated a trend for improved outcomes com-
ared with those assigned to thrombolysis alone.
Thus, a strategy of immediate catheterization followed by
escue PCI for failed thrombolysis has been demonstrated to
e safe, have a high success rate, and improve regional wall
otion and exercise LV function. Moreover, a pooled
nalysis of randomized trials suggested improvement in
evere heart failure, reinfarction, and one-year mortality
14). However, patients requiring rescue PCI remain at
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Editorial Comment July 21, 2004:297–9he PCI is unsuccessful. The high rate of death and
eocclusion may partly be explained by the selection of a
igh-risk group of patients who have already demonstrated
esistance to pharmacologic reperfusion, possibly as a result
f hypotension, large thrombus burden, or platelet-rich
hrombi, factors that are unfavorable to the performance of
CI.
As noted in this issue of the Journal (15), the Middles-
rough Early Revascularization to Limit INfarction (MER-
IN) trial is the largest trial conducted to date of “rescue
ngioplasty.” Unfortunately, this is not a trial of classic
escue PCI, in that patients were randomized very early (60
in after thrombolysis) and were not required to have chest
ain at the time of arrival in the catheterization laboratory
r have an occluded infarct artery. The definition of “failed
hrombolysis” required only the lack of 50% improvement in
he ST-segment elevation, meaning that a patient with only
.5 mm of ST-segment elevation (50% improvement in 1
m of ST-segment elevation) would be eligible for enroll-
ent. On the other hand, the MERLIN trial addresses
mportant clinical questions faced by physicians who use
hrombolytics: Should this patient be transferred to a
ertiary care center? Should this patient undergo emergency
atheterization?
The most serious limitation of the MERLIN trial is the
act that the primary end point is stated to be “mortality.”
lthough the authors themselves gave an estimated range of
ortality of 2% to 12% and commented that 3,000 patients
ould be needed to show a mortality benefit, only 300
atients were enrolled! It is misleading for the authors to
tate that the primary end point is negative, when in fact the
rial was obviously underpowered at the beginning.
An additional concern is that the majority of patients
nrolled were inferior MIs. Randomized trials and Ameri-
an Heart Association/American College of Cardiology
uidelines suggest that the clinical benefit is confined to
nterior MI patients. Despite knowing this, the investiga-
ors did not omit small infarcts, stratify at the time of
andomization for infarct location, or consider this as a
respecified subgroup analysis.
Virtually every thrombolytic and angioplasty trial has
hown an extremely low mortality (typically 2.5%) in pa-
ients with TIMI flow grade 3. Despite numerous patients
aving TIMI flow grade 3 at baseline, the mortality and
omplication rates in the MERLIN trial were quite high.
ven in patients who had no angioplasty because of the
resence of baseline TIMI flow grade 3, mortality was 8%.
urthermore, the majority of reinfarction events in the
escue arm occurred in patients who never underwent rescue
ngioplasty but were treated conservatively.
Why would mortality be higher in the MERLIN trial?
hance may play a role because the study was greatly
nderpowered. The selection of patients with persistent
T-segment elevation despite a patient infarct vessel mayndicate reperfusion injury, hemorrhagic infarction, or mi-rovascular plugging events, none of which can be improved
ith PCI.
The choice of thrombolytics also may be responsible.
treptokinase was the thrombolytic agent used in 90% of
atients enrolled in the MERLIN trial. Randomized trials
f PCI combined with streptokinase or urokinase have
emonstrated increased major adverse cardiac events
MACE) compared with primary angioplasty (1,12,13,16).
owever, several recent studies that used fibrin-specific
hrombolytic agents have shown that early PCI is safe
17–19) and improves MACE compared with conservative
are (20,21).
Increasing data exist that myocardial perfusion may be
bnormal, even in the setting of TIMI grade 3 epicardial
oronary flow. Gibson et al. (22) reviewed 90-min angiog-
aphy in 865 patients treated with fibrin-specific thrombo-
ytic agents in the TIMI-10B trial. They reported that
wo-year survival was predicted not only by TIMI flow
rade but also by improved myocardial perfusion and rescue
CI. Accordingly, many investigations and clinical sites
ave abandoned “rescue angioplasty alone” in lieu of com-
inations of new devices and drugs to stabilize the coronary
umen and improve tissue perfusion. Coronary stenting
auses stabilization of the coronary lumen, resulting in less
ecurrent ischemia, reocclusion, and restenosis (23–25).
bciximab (compared with no abciximab) during rescue
CI after failed fibrin-specific thrombolysis may lower
0-day mortality (26,27). Distal protection during PCI
voids distal embolization and reduces MACE (28). Me-
hanical thrombectomy improves flow, reduces thrombus
urden, and improves MACE (29). Several trials designed
o determine the effectiveness of these new technologies in
atients with AMI have just been completed, and results
ill be available shortly.
Therefore, it is premature to abandon the open-artery
ypothesis. Perhaps the concept of rescue angioplasty is
orrect, but well-designed trials with appropriate patient
election and use of contemporary adjunctive pharmacologic
gents and devices are lacking.
eprint requests and correspondence: Dr. Cindy L. Grines,
ivision of Cardiology, William Beaumont Hospital, 3601 West
3 Mile Road, Royal Oak, Michigan 48073. E-mail: cgrines@
eaumont.edu.
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